Tags

Type your tag names separated by a space and hit enter

[Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients].
Przegl Lek. 2005; 62(1):49-53.PL

Abstract

Continuous subcutaneous insulin infusion (CSII) is used in selected type 1 diabetic subjects to achieve strict blood glucose control. A quarter of a century after its introduction, worldwide use of CSII is increasing. Review of controlled trials shows that, in most patients, mean blood glucose concentrations and glycated hemoglobin percentages are either slightly lower or similar on CSII versus multiple insulin injections. However, hypoglycemia is markedly less frequent than during intensive injection therapy. Ketoacidosis occurs at the same rate. Nocturnal glycemic control is improved with insulin pumps, and automatic basal rate changes help to minimize a pre-breakfast blood glucose increase (the "dawn phenomenon") often seen with injection therapy. Patients with "brittle" diabetes characterized by recurrent ketoacidosis are often not improved by CSII, although there may be exceptions. Insulin pump therapy has been shown to be beneficial in pediatric patients with type 1 diabetes. Our experience with insulin pump therapy in young children, has been positive. Our young patients have had a reduction in HbA1c, mean blood glucose levels, and glycemic excursion; a decrease in episodes of severe hypoglycemia; and an increase in family functioning around diabetes. We believe the success of pump program in young patients can be attributed to the fact that we have employed appropriate criteria for patient selection and have a standardized method to initiate pump therapy and to follow and support our patients/ families. Experience with insulin-pump therapy indicates that candidates for CSII must be strongly motivated to improve self-monitoring of blood glucose, they must also understand and demonstrate use of the insulin pump.

Authors+Show Affiliations

Buczkowska EO
Górnoślaskie Centrum Zdrowia Dziecka i Matki w Katowicach. em.buczkowski@pro.onet.pl
Dworzecki T
No affiliation info available
Wiedermann G
No affiliation info available
Malanowicz B
No affiliation info available
Szot D
No affiliation info available

MeSH

Blood GlucoseControlled Clinical Trials as TopicDiabetes Mellitus, Type 1Diabetic KetoacidosisHumansHypoglycemiaInsulin Infusion SystemsQuality of Life

Pub Type(s)

English Abstract
Journal Article
Review

Language

pol

PubMed ID

16053222

Citation

Buczkowska, Ewa Otto, et al. "[Continuous Subcutaneous Insulin Infusion (CSII) in Treating Young Diabetic Patients]." Przeglad Lekarski, vol. 62, no. 1, 2005, pp. 49-53.
Buczkowska EO, Dworzecki T, Wiedermann G, et al. [Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients]. Przegl Lek. 2005;62(1):49-53.
Buczkowska, E. O., Dworzecki, T., Wiedermann, G., Malanowicz, B., & Szot, D. (2005). [Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients]. Przeglad Lekarski, 62(1), 49-53.
Buczkowska EO, et al. [Continuous Subcutaneous Insulin Infusion (CSII) in Treating Young Diabetic Patients]. Przegl Lek. 2005;62(1):49-53. PubMed PMID: 16053222.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients]. AU - Buczkowska,Ewa Otto, AU - Dworzecki,Tomasz, AU - Wiedermann,Grazyna, AU - Malanowicz,Barbara, AU - Szot,Dorota, PY - 2005/8/2/pubmed PY - 2005/9/24/medline PY - 2005/8/2/entrez SP - 49 EP - 53 JF - Przeglad lekarski JO - Przegl Lek VL - 62 IS - 1 N2 - Continuous subcutaneous insulin infusion (CSII) is used in selected type 1 diabetic subjects to achieve strict blood glucose control. A quarter of a century after its introduction, worldwide use of CSII is increasing. Review of controlled trials shows that, in most patients, mean blood glucose concentrations and glycated hemoglobin percentages are either slightly lower or similar on CSII versus multiple insulin injections. However, hypoglycemia is markedly less frequent than during intensive injection therapy. Ketoacidosis occurs at the same rate. Nocturnal glycemic control is improved with insulin pumps, and automatic basal rate changes help to minimize a pre-breakfast blood glucose increase (the "dawn phenomenon") often seen with injection therapy. Patients with "brittle" diabetes characterized by recurrent ketoacidosis are often not improved by CSII, although there may be exceptions. Insulin pump therapy has been shown to be beneficial in pediatric patients with type 1 diabetes. Our experience with insulin pump therapy in young children, has been positive. Our young patients have had a reduction in HbA1c, mean blood glucose levels, and glycemic excursion; a decrease in episodes of severe hypoglycemia; and an increase in family functioning around diabetes. We believe the success of pump program in young patients can be attributed to the fact that we have employed appropriate criteria for patient selection and have a standardized method to initiate pump therapy and to follow and support our patients/ families. Experience with insulin-pump therapy indicates that candidates for CSII must be strongly motivated to improve self-monitoring of blood glucose, they must also understand and demonstrate use of the insulin pump. SN - 0033-2240 UR - https://www.unboundmedicine.com/medline/citation/16053222/[Continuous_subcutaneous_insulin_infusion__CSII__in_treating_young_diabetic_patients]_ DB - PRIME DP - Unbound Medicine ER -